4-氯-3-甲基-3H-咪唑并[4,5-C]吡啶 | 87034-78-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 4-氯-3-甲基-3H-咪唑并[4,5-C]吡啶
• 英文名称: 4-Chloro-3-methyl-3H-imidazo[4,5-c]pyridine
• 英文别名: 4-chloro-3-methylimidazo[4,5-c]pyridine
• CAS: 87034-78-4
• 化学式: C₇H₆ClN₃
• 分子量: 167.59
• InChiKey: VHLMQGSRUSNLIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氯-3-甲基-3H-咪唑并[4,5-C]吡啶 、 2-氟苄胺 反应 2.0h， 以4-o-fluorobenzylamino-3-methyl-3H-imidazo-(4,5-c)pyridine of m.p. 163°-164° is obtained的产率得到N-[(2-Fluorophenyl)methyl]-3-methyl-3H-imidazo[4,5-c]pyridin-4-amine
  参考文献：
  名称：

  Gaba-agonistic imidazo(4,5-c)pyridines useful as pharmaceuticals

  摘要：

  化合物的名称为imidazo(4,5-c)吡啶，其化学式为##STR1## 其中X为O、S或NH；Y为--NR.sup.2 --CH.dbd.N--或--N.dbd.CH--NR.sup.2 --；R.sup.1为1-苯并噻吩甲基、萘甲基或苄基，可单取代或双取代为F、Cl、NO.sub.2、CF.sub.3或其组合物；R.sup.2为1-4个碳原子的烷基或环丙基甲基，或其生理学上可接受的酸加合物盐，具有重要的药理活性，例如作为GABA激动剂。

  公开号：

  US04654350A1

文献信息

• [EN] FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'HÉTÉROARYLES FUSIONNÉS EN TANT QU'ANTAGONISTES DES RÉCEPTEURS DES ORÉXINES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016101119A1

  公开（公告）日：2016-06-30

  Fused heteroaryl derivative compounds which are antagonists of orexin receptors are provided. The compounds can be used in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. Also provided is a composition which comprises the compound can be use to prevent or treat such diseases in which orexin receptors are involved.

  提供了与异杂环衍生物化合物，这些化合物是促进睡眠的受体拮抗剂。这些化合物可用于潜在治疗或预防涉及促进睡眠的受体的神经和精神疾病。还提供了一种包含该化合物的组合物，可用于预防或治疗涉及促进睡眠的受体的这类疾病。
• Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung
  申请人：MERCK PATENT GmbH

  公开号：EP0082369A1

  公开（公告）日：1983-06-29

  Neue Imidazo(4,5-c)pyridine der allgemeinen Formel I worin X 0, S oder NH, Y -NR2-CH=N- oder -N=CH-NR2-, R1 1-Benzothienyl-methyl, Naphthylmethyl oder ein- oder zweifach durch F, Cl, N02 und/oder CF3 substituiertes Benzyl und R2 Alkyl mit 1 - 4 C-Atomen oder Cyclopropylmethyl bedeuten, sowie deren physiologisch unbedenkliche Säureadditionssalze zeigen selektiv GABA-agonistische und/oder benzodiazepin-antagonistische Wirkungen.

  通式 I 的新型咪唑并(4,5-c)吡啶 其中 X 是 0、S 或 NH Y -NR2-CH=N- 或 -N=CH-NR2-、 R1 1-苯并噻吩甲基、萘甲基或被 F、Cl、N02 和/或 CF3 取代一次或两次的苄基，以及 R2 是含有 1 - 4 个 C 原子的烷基或甲基环丙基、 以及它们对人体无害的酸加成盐具有选择性 GABA 拮抗作用和/或苯并二氮杂卓拮抗作用。
• SHP2 phosphatase inhibitors and methods of use thereof
  申请人：Relay Therapeutics, Inc.

  公开号：US10934302B1

  公开（公告）日：2021-03-02

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

  本公开涉及新型化合物及其药物组合物，以及用本公开的化合物和组合物抑制SHP2磷酸酶活性的方法。本公开进一步涉及但不限于用本公开的化合物和组合物治疗与 SHP2 失调相关的疾病的方法。
• FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20180370973A1

  公开（公告）日：2018-12-27

  The present invention is directed to fused heteroaryl derivative compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
• SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Relay Therapeutics, Inc.

  公开号：US20220340576A1

  公开（公告）日：2022-10-27

  The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.